Ondansetron (injection)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Turky Alkathery, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Ondansetron (injection) is a 5-HT3 receptor antagonist that is FDA approved for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Common adverse reactions include diarrhea, headache, and fever.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Ondansetron (injection) FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ondansetron (injection) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ondansetron (injection) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Ondansetron (injection) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ondansetron (injection) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ondansetron (injection) in pediatric patients.
Contraindications
There is limited information regarding Ondansetron (injection) Contraindications in the drug label.
Warnings
There is limited information regarding Ondansetron (injection) Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Ondansetron (injection) Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Ondansetron (injection) Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Ondansetron (injection) Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Ondansetron (injection) in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ondansetron (injection) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Ondansetron (injection) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Ondansetron (injection) in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Ondansetron (injection) in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Ondansetron (injection) in geriatric settings.
Gender
There is no FDA guidance on the use of Ondansetron (injection) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Ondansetron (injection) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Ondansetron (injection) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Ondansetron (injection) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Ondansetron (injection) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Ondansetron (injection) in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Ondansetron (injection) Administration in the drug label.
Monitoring
There is limited information regarding Ondansetron (injection) Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Ondansetron (injection) and IV administrations.
Overdosage
There is limited information regarding Ondansetron (injection) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Ondansetron (injection) Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Ondansetron (injection) Mechanism of Action in the drug label.
Structure
There is limited information regarding Ondansetron (injection) Structure in the drug label.
Pharmacodynamics
There is limited information regarding Ondansetron (injection) Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Ondansetron (injection) Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Ondansetron (injection) Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Ondansetron (injection) Clinical Studies in the drug label.
How Supplied
There is limited information regarding Ondansetron (injection) How Supplied in the drug label.
Storage
There is limited information regarding Ondansetron (injection) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Ondansetron (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Ondansetron (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Ondansetron (injection) Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Ondansetron (injection) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Ondansetron (injection) Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Ondansetron (injection) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.